{
    "Clinical Trial ID": "NCT00688909",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Letrozole",
        "  Participants received 2.5 milligram (mg) of Letrozole tablets orally once daily (QD) for a period of 24 weeks."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Postmenopausal women with HR+ early stage breast cancer at the time of initial diagnosis. For study purposes, postmenopausal is defined as:",
        "  Age  50 y and amenorrheic for 12 or more months.",
        "  Age  50 y and amenorrheic for 3 or more months after receiving adjuvant chemotherapy.",
        "  Age < 50 y and amenorrheic for 12 or more months.",
        "  Prior bilateral oophorectomy.",
        "  Prior hysterectomy and has postmenopausal levels of FSH, LH, and estradiol as per local institutional standards.",
        "  Age > 55 y and prior hysterectomy.",
        "  Patients who are intolerant and discontinue anastrozole 2-3 weeks prior to study entry when given as adjuvant treatment for HR+ early stage breast cancer due to grade 2-3 (NCI-CTCAE V3) arthralgia-myalgia.",
        "  Hormone receptor-positive tumors as defined by institutional standards.",
        "  ECOG performance status of 0, 1, or 2",
        "  Consent to participate in the trial. -",
        "Exclusion Criteria:",
        "  Postmenopausal women with HR+ metastatic or locally relapsed breast cancer excluding chest wall recurrence with no evidence of systemic disease.",
        "  Recent history of pain associated with non-traumatic bone fracture.",
        "  Pain requiring chronic use of analgesics (due to any reason).",
        "  History of rheumatological disease except osteoarthritis.",
        "  Prior hormonal therapy with AIs other than anastrozole.",
        "  Systemic hormone replacement therapy (HRT) less than 4 weeks before study entry other than Estring\u00ae, Vagifem\u00ae or low dose estrogen vaginal cream.",
        "  Concomitant disease which significantly affects quality of life.",
        "  Patient unable to complete self administered questionnaire.",
        "  Patients unable to sign consent form.",
        "  Other protocol-defined inclusion/exclusion criteria may apply"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Participants Discontinuing Due to Grade 2 or Higher Arthralgia-myalgia.",
        "  The arthralgia status and the myalgia status were separately graded at Baseline (V1), Week 12 (V3) , and Week 24/EOS (V4). The grades of 0 for no pain, 1 for mild pain, 2 for moderate pain, 3 for severe pain, and 4 for disabling pain were used.",
        "  Time frame: End of Study (24 weeks)",
        "Results 1: ",
        "  Arm/Group Title: Letrozole",
        "  Arm/Group Description: Participants received 2.5 milligram (mg) of Letrozole tablets orally once daily (QD) for a period of 24 weeks.",
        "  Overall Number of Participants Analyzed: 261",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  25   9.6%"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 5/261 (1.92%)",
        "  Cholecystitis chronic 1/261 (0.38%)",
        "  Post procedural bile leak 1/261 (0.38%)",
        "  Spinal column stenosis 1/261 (0.38%)",
        "  Depression 1/261 (0.38%)",
        "  Mania 1/261 (0.38%)",
        "  Pulmonary embolism 1/261 (0.38%)"
    ]
}